KMCSHIL138.50

K M C Speciality Hospitals (India) Limited

· Pharma & Health
₹ CrorePeersDRAGARWQKOVAILOTUSEYEGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMED
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Revenue Growth+14.5+13.8
EBITDA Growth+11.1+14.7
EBIT Growth+9.9+13.3
Net Income Growth+12.5+13.8
EPS Growth+13.1+13.4
Total Assets Growth+41.1
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.